CN110105402B - Berberine antitumor platinum (II) complex and synthesis method and application thereof - Google Patents

Berberine antitumor platinum (II) complex and synthesis method and application thereof Download PDF

Info

Publication number
CN110105402B
CN110105402B CN201910495354.0A CN201910495354A CN110105402B CN 110105402 B CN110105402 B CN 110105402B CN 201910495354 A CN201910495354 A CN 201910495354A CN 110105402 B CN110105402 B CN 110105402B
Authority
CN
China
Prior art keywords
complex
berberine
platinum
tfa
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910495354.0A
Other languages
Chinese (zh)
Other versions
CN110105402A (en
Inventor
覃其品
王振凤
黄小玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yulin Normal University
Original Assignee
Yulin Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yulin Normal University filed Critical Yulin Normal University
Priority to CN201910495354.0A priority Critical patent/CN110105402B/en
Publication of CN110105402A publication Critical patent/CN110105402A/en
Application granted granted Critical
Publication of CN110105402B publication Critical patent/CN110105402B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a berberine antitumor platinum (II) complex, a synthesis method thereof and application of the complex in preparing antitumor drugs. The synthetic method of the berberine antitumor platinum (II) complex comprises the following steps: (1) dissolving bromo-berberine derivative, potassium halide and dimethyl pyridylamine in a solvent, and reacting at 90 ℃ to obtain a B-TFA ligand; (2) and (2) dissolving the B-TFA ligand prepared in the step (1) and dichloro-bis (dimethyl sulfoxide) platinum (II) in an acetonitrile solution, carrying out coordination reaction for 4-6 hours, and washing and drying a product to obtain the compound. The invention synthesizes the platinum complex by taking the bromo-berberine derivative B-TFA as an active ligand for the first time, shows excellent in-vivo and in-vitro anti-tumor activity and targeting property, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments. The structural formula of the berberine anti-tumor platinum (II) complex is as follows:
Figure DDA0003127901830000011

Description

Berberine antitumor platinum (II) complex and synthesis method and application thereof
Technical Field
The invention relates to a platinum high-activity complex and a synthetic method thereof, in particular to a berberine anti-tumor platinum (II) complex and a synthetic method thereof. The invention also relates to the application of the berberine antitumor platinum (II) complex in preparing antitumor drugs.
Background
Since cisplatin was discovered, 4 anticancer drugs of nedaplatin, oxaliplatin, sulplatin and leplatin were listed in succession, but it was still unsatisfactory in improving the therapeutic effect, reducing the toxic and side effects and overcoming the cross-resistance. Scientists and researchers have tried to synthesize a new platinum antitumor complex by performing various structural modifications on platinum, and hopefully, the attempts have led to finding a platinum anticancer drug with higher activity and lower toxicity.
The main chemical component of the fibraurea recisa pierre is fibraurea recisa pierre alkaloid which is mainly distributed in areas such as Guangxi, Yunnan and Guangdong, and is one of the main sources of berberine or berberine. At present, berberine is verified to have the effects of anti-tumor, anti-inflammatory, antibacterial, immunity enhancement, nerve protection, anti-depression activity, blood fat reduction and the like. Hitherto, no related reports exist on the research of synthesizing the metal complex and the action mechanism thereof by taking berberine derivatives as the ligands of the active ingredients of the traditional Chinese medicine. Therefore, designing and searching the berberine anti-tumor rare earth metal complex with high water solubility, high curative effect, low toxic and side effects and strong targeting becomes a problem to be solved at present.
Disclosure of Invention
The first object of the present invention is to provide a berberine anti-tumor platinum (II) complex.
In order to achieve the first object of the present invention, the present invention provides the following technical solutions:
a berberine anti-tumor platinum (II) complex has the following chemical structural formula:
Figure GDA0003127901820000021
the second purpose of the invention is to provide a synthetic method of a berberine anti-tumor platinum (II) complex.
In order to achieve the second object of the present invention, the present invention provides the following technical solutions:
a synthetic method of a berberine anti-tumor platinum (II) complex comprises the following steps:
(1) dissolving bromo-berberine derivative, potassium halide and dimethyl pyridylamine in a solvent, and reacting at 90 ℃ to obtain a B-TFA ligand;
(2) and (2) dissolving the B-TFA ligand prepared in the step (1) and dichloro-bis (dimethyl sulfoxide) platinum (II) in an acetonitrile solution, carrying out coordination reaction for 4-6 hours, and washing and drying a product to obtain the compound.
Further, the solvent in the step (1) is acetonitrile.
Further, the molar ratio of the bromo-berberine derivative to the potassium halide to the dimethyl pyridylamine is 1:0.8: 1.5-3.2.
Further, the method is characterized in that the reaction time of the step (1) is 12-15 hours.
Further, the reaction temperature of the step (2) is 55-65 ℃.
Further, the volume of the acetonitrile solution in the step (2) is 10-75 mL.
The third purpose of the invention is to provide the application of the berberine antitumor platinum (II) complex in preparing antitumor drugs.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention firstly takes a bromo-berberine derivative B-TFA as an active ligand to synthesize the platinum complex [ Pt (B-TFA) Cl ] Cl (wherein TFA is trifluoroacetic acid), and the synthesis route is simple, the reaction condition is mild, and the yield is high.
2. The invention researches the activity and toxicity experiments of the complex on T-24, SK-OV-3/DDP, A549 tumor cells and normal HL-7702 cells. Experimental results show that the complex has good inhibition effect on human tumor cells, and the IC50 value is 0.1-15.2 mu M; particularly, the compound has better inhibiting effect on human bladder cancer cell T-24, the IC50 values are 0.1 +/-0.1 mu M respectively, and the in vitro anti-tumor activity of the compound is far greater than that of a clinical classical metal-based anti-cancer medicament cisplatin 10.4 +/-1.2 mu M.
3. The berberine anti-tumor platinum (II) complex and the Pt1 complex have little toxicity (IC50 is more than 150 mu M) to normal cells HL-7702, and show good effect of targeted inhibition of proliferation of human bladder cancer cells. In a word, the complex Pt1 shows excellent in-vivo and in-vitro anti-tumor activity and targeting property, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments.
4. When the berberine antitumor platinum (II) complex is synthesized, the reaction can be carried out only if the mass ratio of the bromo-berberine derivative to the dimethyl pyridylamine is 1: 1.5-3.2; the reaction temperature is 90 ℃, the product is adhered to the bottom and generates carbon chain breakage at the temperature higher than 90 ℃, and the reaction hardly occurs at the temperature lower than 90 ℃.
Drawings
The technical solutions of the present invention are further described in detail with reference to the specific embodiments in the drawings, but the present invention is not limited thereto.
FIG. 1 is an electrospray mass spectrum of B-TFA prepared in example 1 of the present invention;
FIG. 2 is a hydrogen nuclear magnetic resonance spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 3 is a nuclear magnetic resonance carbon spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 4 is a nuclear magnetic resonance fluorine spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 5 is an electrospray mass spectrum of a complex Pt1 prepared in example 1 of the present invention;
FIG. 6 is a NMR spectrum of Pt1 obtained in example 1 of the present invention;
FIG. 7 is a NMR carbon spectrum of Pt1 obtained in example 1 of the present invention;
FIG. 8 shows the nuclear magnetic resonance fluorine spectrum of Pt1 obtained in example 1 of the present invention.
Detailed Description
The raw material bromo-berberine derivative 1 related in the embodiment of the invention is prepared by referring to the existing literature (Huang, Z. -S.; et al. bioorgan. Med. chem.,2008,16, 7582-7591.); in addition, platinum (II) bis (dimethyl sulfoxide) dichloride can be prepared by referring to the existing literature (Al-Allaf, T.A.K.; et Al. Transit. Met. chem.,1998,23:403-406.) which is abbreviated as cis-PtCl2(DMSO)2
Example 1
1.0mol of derivative 1, 0.8mol of potassium iodide and 3.20mol of lutidine are respectively weighed in a high-temperature pressure-resistant tube, 5.0ml of acetonitrile is added, the added solvent is just finished to dissolve the solid, so that the reaction is more complete, and after the reaction is carried out for 12 hours at 90 ℃, yellow solid powder B-TFA ligand is obtained, wherein the yield is 94.0%.
Weighing 1.0mol of ligand B-TFA and 1.0mol of dichloro-bis (dimethyl sulfoxide) platinum (II), placing the ligand B-TFA and 1.0mol of dichloro-bis (dimethyl sulfoxide) platinum (II) into a 100.0mL high-temperature pressure-resistant bottle, adding 25.0mL of acetonitrile solution, carrying out coordination reaction at 60 ℃ for 4.0h, washing with acetonitrile, and drying in vacuum at 45 ℃ to obtain a yellow target product Pt 1. The yield was 90.8%.
The synthetic route of the berberine anti-tumor platinum (II) complex is as follows:
Figure GDA0003127901820000051
example 2
The difference from example 1 is that ligand B-TFA (1.0mol) and platinum (II) bis (dimethyl sulfoxide) (1.0mol) dichloride are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 10.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and dried in vacuum at 45 ℃, and then the yellow target product Pt1 is obtained. The yield was 85.6%.
Example 3
The difference from example 1 is that ligand B-TFA (1.0mol) and platinum (II) bis (dimethyl sulfoxide) (1.0mol) dichloride are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 75.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and dried in vacuum at 45 ℃, and then the yellow target product Pt1 is obtained. The yield was 80.0%.
Example 4
The difference from example 1 is that ligand B-TFA (1.0mol) and dichloro-bis (dimethyl sulfoxide) platinum (II) (1.0mol) are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 40.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and then dried in vacuum at 45 ℃, and then yellow target product Pt1 is obtained. The yield was 89.1%.
Experimental example 1
To further determine the structure of the ligands and complexes, the structure of the product of example 1 was characterized.
1. Identification of the resulting B-TFA
(1) Electrospray mass spectrometry, the spectrum of which is shown in figure 1.
ESI-MS M/z 645.3[ M- (TFA-H) ] +, where M is the molecular weight of Compound B-TFA.
(2) The NMR spectrum is shown in FIG. 2.
1H NMR(400MHz,CHCl3-d)δ9.84(s,1H),8.81(d,J=5.5Hz,2H),8.26-8.20(m,2H),8.20-8.16(m,1H),7.87(dd,J=4.7,8.3Hz,3H),7.82-7.76(m,1H),7.67(t,J=6.5Hz,2H),7.36(s,1H),6.85(s,1H),6.11(s,2H),5.01(br t,J=5.8Hz,2H),4.42(s,4H),4.36(t,J=6.7Hz,2H),4.06(s,3H),3.29-3.20(m,2H),2.87-2.77(m,2H),1.93-1.82(m,2H),1.65-1.52(m,2H),1.48-1.39(m,2H),1.34-1.29(m,2H),1.23(br s,6H)。
(3) NMR spectrum of carbon, as shown in FIG. 3.
13C NMR(400MHz,DMSO-d6)δ158.925-158.561(m,2C),150.810(s,1C),150.416-149.847(m,1C),149.001(s,2C),147.711(s,1C),145.275(s,1C),142.927(s,1C),137.889-137.473(s,2C),130.648(s,1C),126.674(s,1C),124.990(s,1C),124.122(s,1C),123.306(s,1C),121.687(s,1C),120.447(s,1C),120.236(s,1C),117.399(s,1C),114.490(s,1C),108.380(s,1C),105.426(s,1C),102.080(s,1C),74.265(s,1C),56.981-56.769(m,3C),55.318(s,1C),53.926(s,1C),29.469(s,1C),28.711–28.390(m,2C),26.363(s,1C),25.904(s,1C),25.226(s,1C),23.191(s,1C)。
(4) NMR spectrum of fluorine as shown in FIG. 3.
19F NMR(471MHz,CHCl3)δ-75.804。
(5) The results of elemental analysis are shown in Table 1.
Table 1 elemental analysis results of Compounds B-TFA and Pt1 in the examples
Figure GDA0003127901820000071
Thus, the yellow target product was identified as compound B-TFA, having the formula:
Figure GDA0003127901820000072
2. the obtained complex Pt1 is identified
(1) Electrospray mass spectrometry, the spectrum of which is shown in FIG. 5.
ESI-MS m/z:987.4[M-Cl]+Wherein M is the molecular weight of the complex Pt 1.
(2) The NMR spectrum is shown in FIG. 6.
1H NMR(500MHz,DMSO-d6)δ9.72(s,1H),8.92(s,1H),8.77(d,J=5.3Hz,2H),8.31(t,J=7.2Hz,2H),8.23–8.09(m,1H),7.99(s,1H),7.85(s,2H),7.75(s,1H),7.67(t,J=6.6Hz,2H),7.08(s,1H),6.18(s,2H),5.37(s,2H),4.94(d,J=31.1Hz,4H),4.24(t,J=6.4Hz,2H),4.04(s,3H),3.05(s,2H),2.52(s,2H),1.90-1.75(m,2H),1.51(s,2H),1.40(t,J=7.9Hz,2H),1.31–1.20(m,4H),1.16(d,J=14.4Hz,4H)。
(3) NMR spectrum of carbon, as shown in FIG. 7.
13C NMR(126MHz,DMSO-d6)δ166.31,158.44,158.19,150.84,150.23,149.43,148.10,145.73,143.29,141.82,137.85,133.44,131.07,127.07,125.85,123.99,123.82,122.10,120.88,120.70,108.89,105.86,102.57,74.72,68.50,64.81,57.53,55.84,40.56,40.39,40.23,40.06,39.89,39.72,39.56,29.93,29.25,29.10,29.03,27.58,26.86,26.31,25.64。
(4) NMR spectrum of the product shown in FIG. 8.
19F NMR(471MHz,DMSO-d6)δ-73.52。
(5) The results of elemental analysis are shown in Table 1.
Thus, the resulting yellow target product was identified as complex Pt1, having the formula:
Figure GDA0003127901820000081
experimental example 2
In order to fully illustrate the application of the berberine antitumor platinum (II) complex Pt1 in pharmacy, in-vivo and in-vitro antitumor activity experiments are carried out on the berberine antitumor platinum (II) complex.
Experiment on proliferation inhibition activity of platinum (II) complex Pt1 on various human tumor cell lines
1. Cell lines and cell cultures
4 human cell strains such as human ovarian cancer cisplatin-resistant SK-OV-3/DDP cells, human bladder cancer T-24 cells, human bladder cancer A549 cells, human normal liver HL-7702 cells and the like are selected for the experiment.
All human cell lines were cultured in RPMI-1640 medium containing 100U/mL penicillin, 10 wt% calf blood, and 100U/mL streptomycin, and placed at 37 deg.C with 5% CO by volume2Culturing in an incubator.
2. Preparation of test Compounds
The ligands B-TFA and Pt1 used were all 95% pure, their DMSO stock solutions were diluted with physiological buffer to 20. mu. mol/L final solution (DMSO final concentration. ltoreq.1%) at which the degree of inhibition of growth of normal cells or selected tumor cells by each compound was tested.
3. Cell growth inhibition assay (MTT method)
(1) Taking normal cells or tumor cells in a logarithmic growth phase, digesting the cells or tumor cells by trypsin, preparing a cell suspension with the concentration of 5000/mL by using a culture solution containing 10% calf serum, inoculating 190 mu L of the cell suspension into a 96-hole culture plate, and enabling the density of cells to be detected to reach 1000-10000 holes (the edge holes are filled with sterile PBS);
(2)5%CO2incubating for 24h at 37 ℃ until a cell monolayer is paved on the bottom of each well, adding 10 mu L of medicine with a certain concentration gradient into each well, and arranging 4 compound wells in each concentration gradient;
(3)5%CO2incubating at 37 ℃ for 48 hours, and observing under an inverted microscope;
(4) add 10. mu.L of MTT solution (5mg/mL PBS, i.e., 0.5% MTT) to each well and continue culturing for 4 h;
(5) terminating the culture, carefully removing the culture solution in the wells, adding 150 μ L of DMSO into each well to sufficiently dissolve formazan precipitate, mixing uniformly with an oscillator, and measuring the optical density of each well with a microplate reader at a wavelength of 570nm and a reference wavelength of 450 nm;
(6) simultaneously, a zero setting hole (culture medium, MTT, DMSO) and a control hole (cells, culture solution, MTT, a drug dissolving medium with the same concentration, DMSO) are arranged.
(7) The number of living cells was judged from the measured optical density values (OD values), and the larger the OD value, the stronger the cell activity. Using the formula:
Figure GDA0003127901820000091
calculating the inhibition rate of each compound on the growth of the selected cells, and calculating the IC of each tested compound on each selected cell strain by a Bliss method50The value is obtained. The results are shown in table 2 below.
TABLE 2 IC of Compounds on various cell lines50Value (μ M)
Figure GDA0003127901820000101
Slave IC50According to the result of activity screening, the proliferation inhibition activity of the complex Pt1 on three tested human tumor cell strains SK-OV-3/DDP, T-24 and A549 cells is obviously higher than that of cis-Pt (DMSO) of metal salt2Cl2And ligands B-TFA and TFA thereof, which embody the synergistic effect of ligand B-TFA and a platinum central atom. Wherein the complex Pt1 has better inhibiting effect on T-24 cells and IC thereof50The value is 0.1 +/-0.1 mu M, and the in vitro anti-tumor activity of the compound is far greater than that of a clinical classical metal-based anti-cancer medicament cisplatin (10.4 +/-1.2 mu M); furthermore, the Pt1 complex has little toxicity (IC) to HL-7702 which is a normal cell50The value is more than 150 mu M), and the compound shows good effect of targeted inhibition of bladder cancer cell proliferation. In a word, the complex Pt1 shows excellent in-vitro anti-tumor activity and targeting selectivity on tumor cells, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments.
The above description is part of the embodiments of the present invention, and is not intended to limit the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the principles of the invention.

Claims (2)

1. A berberine anti-tumor platinum (II) complex has the following chemical structural formula:
Figure FDA0003127901810000011
2. the use of the berberine anti-tumor platinum (II) complex of claim 1 in the preparation of an anti-tumor medicament for treating ovarian cancer or bladder cancer.
CN201910495354.0A 2019-06-10 2019-06-10 Berberine antitumor platinum (II) complex and synthesis method and application thereof Active CN110105402B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910495354.0A CN110105402B (en) 2019-06-10 2019-06-10 Berberine antitumor platinum (II) complex and synthesis method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910495354.0A CN110105402B (en) 2019-06-10 2019-06-10 Berberine antitumor platinum (II) complex and synthesis method and application thereof

Publications (2)

Publication Number Publication Date
CN110105402A CN110105402A (en) 2019-08-09
CN110105402B true CN110105402B (en) 2021-09-07

Family

ID=67494374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910495354.0A Active CN110105402B (en) 2019-06-10 2019-06-10 Berberine antitumor platinum (II) complex and synthesis method and application thereof

Country Status (1)

Country Link
CN (1) CN110105402B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108659051A (en) * 2018-05-07 2018-10-16 玉林师范学院 A kind of high activity cumarin targeting oophoroma-platinum (II) complex and its synthetic method and application
CN108774270A (en) * 2018-07-20 2018-11-09 玉林师范学院 Target Sorafenib anti-tumor platinum (II) complex and the preparation method and application thereof of human lung cancer mdr cell
CN108774269A (en) * 2018-07-20 2018-11-09 玉林师范学院 Novel targeted benzimidazoles derivative anti-tumor platinum (II) and ruthenium (II) complex and the preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108659051A (en) * 2018-05-07 2018-10-16 玉林师范学院 A kind of high activity cumarin targeting oophoroma-platinum (II) complex and its synthetic method and application
CN108774270A (en) * 2018-07-20 2018-11-09 玉林师范学院 Target Sorafenib anti-tumor platinum (II) complex and the preparation method and application thereof of human lung cancer mdr cell
CN108774269A (en) * 2018-07-20 2018-11-09 玉林师范学院 Novel targeted benzimidazoles derivative anti-tumor platinum (II) and ruthenium (II) complex and the preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1;Yane Xiang Wang et al.;《European Journal of Medicinal Chemistry》;20171111;1858-1868页 *

Also Published As

Publication number Publication date
CN110105402A (en) 2019-08-09

Similar Documents

Publication Publication Date Title
CN107746418B (en) Synthesis and application of 9-chloro-1, 2,3, 4-tetrahydroacridine-platinum (II) complex targeting liver cancer
CN108774270B (en) Sorafenib antitumor platinum (II) complex targeting drug-resistant cells of human lung cancer and preparation method and application thereof
CN110950914B (en) Iridium complex and synthesis method and application thereof
CN111187303B (en) Platinum (II) complex with high antitumor activity of cryptolepine, and synthetic method and application thereof
CN110054652B (en) Jatrorrhizine platinum (II) complex and synthesis method and application thereof
CN111039990B (en) Low-toxicity iridium complex and synthesis method and application thereof
CN108774269B (en) Novel targeted benzimidazole derivative antitumor platinum (II) and ruthenium (II) complex and preparation method and application thereof
CN111153916A (en) White leaf vine zinc (II) complex and synthesis method and application thereof
CN111205311A (en) Novel high-antitumor-activity white leaf vine zinc (II) complex and synthesis method and application thereof
CN110330534B (en) Novel 2-phenylpyridine-platinum (IV) precursor anticancer complex and synthesis method and application thereof
CN111253418A (en) Novel white leaf vine zinc (II) complex and synthesis method and application thereof
CN111116667B (en) Iridium complex constructed based on 8-hydroxyquinoline derivative and 1-phenylpyrazole iridium dimer as well as synthetic method and application thereof
CN110105402B (en) Berberine antitumor platinum (II) complex and synthesis method and application thereof
CN114539294B (en) Cisplatin-resistant cell white rattan-phenanthrene Luo Linxin (II) complex for targeting human lung adenocarcinoma, synthesis method and application thereof
CN110172075B (en) Novel coumarin-quinoline-platinum (II) complex and synthesis method and application thereof
CN114573598B (en) White She Tengxin (II) complex with high in-vivo and in-vitro activity and synthesis method and application thereof
CN107827934B (en) Tetravalent platinum complex with anticancer activity, preparation method and application
CN110054651B (en) Targeted human bladder cancer jatrorrhizine platinum (II) complex and synthesis method and application thereof
CN108997436B (en) Rueglini antitumor platinum (II) complex and preparation method and application thereof
CN110156842B (en) Coumarin-platinum (II) complex targeting lung cancer drug-resistant strain and synthesis method and application thereof
CN108456231B (en) Bis-halo coumarin-platinum (II) complex and synthesis method and application thereof
CN114409707B (en) 8-hydroxyquinoline-N-oxide manganese complex and synthetic method and application thereof
CN115385940B (en) Zinc (II) complex of sinomenine and application thereof
CN115160347B (en) Glycosyl white vine zinc (II) complex and application
CN117551136A (en) 4-phenyl-2, 6-bis (2' -pyrazinyl) pyridine binuclear platinum complex, synthesis method and application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20190809

Assignee: Guangxi Xinghui Technology Co.,Ltd.

Assignor: Yulin Normal University

Contract record no.: X2022450000344

Denomination of invention: A Berberine Antitumor Platinum (II) Complex and Its Synthesis and Application

Granted publication date: 20210907

License type: Common License

Record date: 20221219

EE01 Entry into force of recordation of patent licensing contract